公开(公告)号：EP2968611A1

公开(公告)日：2016-01-20

申请号：EP14774631.7

申请日：2014-03-13

申请人： The Administrators of the Tulane Educational Fund ,  Autoimmune Technologies, LLC

发明人： GARRY, Robert, F. ,  BRANCO, Luis, M. ,  BUNNELL, Bruce, A. ,  WILSON, Russell, B. ,  HOPKINS, Samuel, E.

IPC分类号： A61K48/00 ,  C12N5/077 ,  C12N15/86

CPC分类号： A61K39/42 ,  A61K35/28 ,  C07K16/10 ,  C07K2317/76 ,  C12N5/0667 ,  C12N2510/00 ,  G01N33/6854 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393 ,  Y02A50/395 ,  Y02A50/402 ,  Y02A50/406 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/421 ,  Y02A50/423 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/469 ,  Y02A50/471 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/48 ,  Y02A50/481 ,  Y02A50/491

摘要： Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFNα, IFN&bgr;, or IFNω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.

公开(公告)号：EP2478103A2

公开(公告)日：2012-07-25

申请号：EP10817783.3

申请日：2010-09-15

申请人： The Administrators of the Tulane Educational Fund

发明人： BRANCO, Luis, M. ,  GARRY, Robert F.

IPC分类号： C12N15/40 ,  C12N7/01 ,  A61K39/12 ,  A61P31/14 ,  C12Q1/70

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K2039/5258 ,  C12N2760/10022 ,  C12N2760/10023 ,  C12N2760/10034

摘要： The instant invention is directed to novel Lassa virus-like particle (VLP) compositions and methods of production thereof. The inventive VLPs comprise, for example, the Lassa virus (LASV) Z matrix protein, glycoproteins (GPs)-I and -2, and nucleoprotein (NP). A novel method for producing these VLPs comprises constructing multicistronic plasmids for the expression of VLP protein components from a single vector. One example is a tricistronic vector containing DNA sequences encoding the LASV Z, GPC and NP proteins. The VLPs provided by the present invention can be used for research, therapeutic and diagnostic purposes.

公开(公告)号：EP2155777A2

公开(公告)日：2010-02-24

申请号：EP08742716.7

申请日：2008-04-10

申请人： The Administrators of the Tulane Educational Fund

发明人： BRANCO, Luis, M. ,  MATSCHINER, Alexander ,  ILLICK, Megan, M. ,  SAMPEY, Darryl, B. ,  GARRY, Robert, F. ,  BAUSCH, Daniel, G. ,  FAIR, Joseph, N. ,  GUTTIERI, Mary, C. ,  CASHMAN, Kathleen, A. ,  WILSON, Russell, B. ,  KULAKOSKY, Peter, C. ,  GESKE, F., Jon

IPC分类号： C07K14/08 ,  A61K38/16 ,  A61K39/12

CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K16/10 ,  C07K2319/24 ,  C07K2319/30 ,  C12N2760/10022 ,  C12N2760/10033 ,  G01N33/56983 ,  G01N2333/08

摘要： The invention discloses compositions comprising soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins. This invention further relates to diagnostic and preventative methods using these compositions. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules) that inhibit LASV infectivity. Further, the invention relates to diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses.